Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1958 1
1959 1
1965 3
1967 1
1968 2
1969 2
1970 4
1972 1
1973 2
1975 1
1976 1
1977 2
1978 1
1979 2
1980 1
1982 1
1989 1
1990 1
1992 2
1993 2
1994 2
1995 1
1996 3
1997 1
1998 1
1999 3
2000 3
2001 1
2002 3
2003 5
2004 3
2005 3
2006 5
2007 2
2008 1
2010 1
2012 3
2013 3
2014 3
2015 6
2016 8
2017 12
2018 7
2019 16
2020 18
2021 30
2022 21
2023 30
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

216 results

Results by year

Filters applied: . Clear all
Page 1
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, Coeck C, Clerisme-Beaty E, Rosenstock B, Quaresma M, Haeufel T, Goeldner RG, Schlenker-Herceg R, Brown KK; INBUILD Trial Investigators. Flaherty KR, et al. N Engl J Med. 2019 Oct 31;381(18):1718-1727. doi: 10.1056/NEJMoa1908681. Epub 2019 Sep 29. N Engl J Med. 2019. PMID: 31566307 Clinical Trial.
Idiopathic Pulmonary Fibrosis (IPF): An Overview.
Barratt SL, Creamer A, Hayton C, Chaudhuri N. Barratt SL, et al. Among authors: chaudhuri n. J Clin Med. 2018 Aug 6;7(8):201. doi: 10.3390/jcm7080201. J Clin Med. 2018. PMID: 30082599 Free PMC article. Review.
The therapy of idiopathic pulmonary fibrosis: what is next?
Somogyi V, Chaudhuri N, Torrisi SE, Kahn N, Müller V, Kreuter M. Somogyi V, et al. Among authors: chaudhuri n. Eur Respir Rev. 2019 Sep 4;28(153):190021. doi: 10.1183/16000617.0021-2019. Print 2019 Sep 30. Eur Respir Rev. 2019. PMID: 31484664 Free PMC article. Review.
Drug-Induced Interstitial Lung Disease: A Systematic Review.
Skeoch S, Weatherley N, Swift AJ, Oldroyd A, Johns C, Hayton C, Giollo A, Wild JM, Waterton JC, Buch M, Linton K, Bruce IN, Leonard C, Bianchi S, Chaudhuri N. Skeoch S, et al. Among authors: chaudhuri n. J Clin Med. 2018 Oct 15;7(10):356. doi: 10.3390/jcm7100356. J Clin Med. 2018. PMID: 30326612 Free PMC article. Review.
An update on interstitial lung disease.
Mudawi D, Heyes K, Hastings R, Rivera-Ortega P, Chaudhuri N. Mudawi D, et al. Among authors: chaudhuri n. Br J Hosp Med (Lond). 2021 Jul 2;82(7):1-14. doi: 10.12968/hmed.2020.0556. Epub 2021 Jul 20. Br J Hosp Med (Lond). 2021. PMID: 34338019
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial.
Maher TM, Tudor VA, Saunders P, Gibbons MA, Fletcher SV, Denton CP, Hoyles RK, Parfrey H, Renzoni EA, Kokosi M, Wells AU, Ashby D, Szigeti M, Molyneaux PL; RECITAL Investigators. Maher TM, et al. Lancet Respir Med. 2023 Jan;11(1):45-54. doi: 10.1016/S2213-2600(22)00359-9. Epub 2022 Nov 11. Lancet Respir Med. 2023. PMID: 36375479 Free article. Clinical Trial.
Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study.
Solomon JJ, Danoff SK, Woodhead FA, Hurwitz S, Maurer R, Glaspole I, Dellaripa PF, Gooptu B, Vassallo R, Cox PG, Flaherty KR, Adamali HI, Gibbons MA, Troy L, Forrest IA, Lasky JA, Spencer LG, Golden J, Scholand MB, Chaudhuri N, Perrella MA, Lynch DA, Chambers DC, Kolb M, Spino C, Raghu G, Goldberg HJ, Rosas IO; TRAIL1 Network Investigators. Solomon JJ, et al. Among authors: chaudhuri n. Lancet Respir Med. 2023 Jan;11(1):87-96. doi: 10.1016/S2213-2600(22)00260-0. Epub 2022 Sep 5. Lancet Respir Med. 2023. PMID: 36075242 Clinical Trial.
Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M; INBUILD trial investigators. Wells AU, et al. Lancet Respir Med. 2020 May;8(5):453-460. doi: 10.1016/S2213-2600(20)30036-9. Epub 2020 Mar 5. Lancet Respir Med. 2020. PMID: 32145830 Clinical Trial.
216 results